Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 2/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 2/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.77 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.67 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.67 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.66 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004733 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL4176661 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8049183 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL16431424 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23992003 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL12171707 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL23668326 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8388177 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL8048373 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 | |
| SCHEMBL2502820 | 1.00 | PRKCA (1.00) | PRKCAPRKCEPRKCQPRKCDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. | 2023-06-22 | — | — | US | claimed |
| WO-2021188564-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | FIRST WAVE BIO, INC. (US) | 2021-09-23 | — | — | WO | claimed |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FIRST WAVE BIO, INC. (US) | 2020-09-15 | — | — | US | claimed |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | MONTERESEARCH S.R.L. (IT) | 2019-10-03 | — | — | US | claimed |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FIRST WAVE BIO, INC. (US) | 2019-05-21 | — | — | US | claimed |
| US-6974832-B2 | L-ascorbic acid and pectin composition | DSM NUTRITIONAL PRODUCTS INC. (US) | 2005-12-13 | — | — | US | claimed |
| US-20240122903-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2024-04-18 | — | — | US | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| US-20240100017-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2024-03-28 | — | — | US | disclosed |
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2024-03-07 | — | — | US | disclosed |
| US-20240060982-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2024-02-22 | — | — | US | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| US-20240041843-A1 | METHODS OF TREATING CANCER | NOVARTIS PHARMA AG (CH) | 2024-02-08 | — | — | US | disclosed |
| WO-2019023145-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | IFM Tre, Inc. (US) | 2019-01-31 | — | — | WO | disclosed |
| EP-3344274-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Bio, Inc. (US) | 2018-07-11 | — | — | EP | disclosed |
| WO-2017040864-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | First Wave Biopharma (US) | 2017-03-09 | — | — | WO | disclosed |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FIRST WAVE BIO, INC. | 2017-03-02 | — | — | US | disclosed |
| US-20070116757-A1 | Methylene Blue Derivatives | COLLEGIUM PHARMACEUTICAL, INC. | 2007-05-24 | — | — | US | disclosed |
| EP-0422490-A2 | Triglycerides containing saturated fatty acids having 20 to 24 carbon atoms useful in lowering blood cholesterol levels | THE PROCTER & GAMBLE COMPANY (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4883684-A | SHORTENING CONTAINING MIXTURE OF TRIGLYCERIDES | THE PROCTER & GAMBLE COMPANY (US) | 1989-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074995-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PRKCA 3159/4885PRKCE 3655/4885PRKCQ 3611/4885 |
| US-20240060982-A1 | METHODS OF TREATING CANCER | STING1, CGAS, ATM | PRKCA 465/4885PRKCE 791/4885PRKCQ 1015/4885 |
| US-20190298670-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PRKCA 3157/4885PRKCE 3661/4885PRKCQ 3604/4885 |
| US-20230190684-A1 | METHODS OF TREATING COVID-19 WITH A NICLOSAMIDE COMPOUND | ACE2, ACE, MME | PRKCA 4843/4885PRKCE 4820/4885PRKCQ 4863/4885 |
| US-10292951-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory responses | FH, CS, ECHS1 | PRKCA 3157/4885PRKCE 3661/4885PRKCQ 3604/4885 |
| US-20240100017-A1 | METHODS OF TREATING CANCER | STING1, CGAS, MRE11 | PRKCA 950/4885PRKCE 1457/4885PRKCQ 1506/4885 |
| US-20070116757-A1 | Methylene Blue Derivatives | ACMSD, SI, HTR2B | PRKCA 4312/4885PRKCE 3919/4885PRKCQ 4705/4885 |
| US-20240041843-A1 | METHODS OF TREATING CANCER | STING1, CGAS, TBK1 | PRKCA 484/4885PRKCE 737/4885PRKCQ 823/4885 |
| US-20170056347-A1 | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH AN ABNORMAL INFLAMMATORY RESPONSES | FH, CS, ECHS1 | PRKCA 3157/4885PRKCE 3661/4885PRKCQ 3604/4885 |
| US-20240122903-A1 | METHODS OF TREATING CANCER | STING1, CGAS, DDX3X | PRKCA 818/4885PRKCE 1730/4885PRKCQ 1256/4885 |
| US-10772854-B2 | Methods and compositions for treating conditions associated with an abnormal inflammatory response | FH, CS, ECHS1 | PRKCA 3216/4885PRKCE 3698/4885PRKCQ 3687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.